These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

204 related items for PubMed ID: 27890446

  • 1. Efficacy of Therapies After Galeterone in Patients With Castration-resistant Prostate Cancer.
    McKay RR, Werner L, Fiorillo M, Roberts J, Heath EI, Bubley GJ, Montgomery RB, Taplin ME.
    Clin Genitourin Cancer; 2017 Aug; 15(4):463-471. PubMed ID: 27890446
    [Abstract] [Full Text] [Related]

  • 2. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.
    Pezaro CJ, Omlin AG, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D, Dearnaley D, Parker C, de Bono JS, Attard G.
    Eur Urol; 2014 Sep; 66(3):459-65. PubMed ID: 24411987
    [Abstract] [Full Text] [Related]

  • 3. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
    Taplin ME, Antonarakis ES, Ferrante KJ, Horgan K, Blumenstein B, Saad F, Luo J, de Bono JS.
    Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
    [Abstract] [Full Text] [Related]

  • 4. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.
    JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
    [Abstract] [Full Text] [Related]

  • 5. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
    Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y.
    Eur Urol; 2015 Aug; 68(2):228-35. PubMed ID: 24837187
    [Abstract] [Full Text] [Related]

  • 6. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
    Brasso K, Thomsen FB, Schrader AJ, Schmid SC, Lorente D, Retz M, Merseburger AS, von Klot CA, Boegemann M, de Bono J.
    Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579
    [Abstract] [Full Text] [Related]

  • 7. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone.
    Schrader AJ, Boegemann M, Ohlmann CH, Schnoeller TJ, Krabbe LM, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann E, Cronauer MV.
    Eur Urol; 2014 Jan; 65(1):30-6. PubMed ID: 23849416
    [Abstract] [Full Text] [Related]

  • 8. Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-naïve castration-resistant prostate cancer: The Kyoto-Baltimore collaboration.
    Terada N, Maughan BL, Akamatsu S, Kobayashi T, Yamasaki T, Inoue T, Kamba T, Ogawa O, Antonarakis ES.
    Int J Urol; 2017 Jun; 24(6):441-448. PubMed ID: 28455853
    [Abstract] [Full Text] [Related]

  • 9. Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.
    Zhang T, Dhawan MS, Healy P, George DJ, Harrison MR, Oldan J, Chin B, Armstrong AJ.
    Clin Genitourin Cancer; 2015 Aug; 13(4):392-399. PubMed ID: 25708161
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.
    Azad AA, Eigl BJ, Murray RN, Kollmannsberger C, Chi KN.
    Eur Urol; 2015 Jan; 67(1):23-29. PubMed ID: 25018038
    [Abstract] [Full Text] [Related]

  • 11. Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate.
    Thomsen FB, Røder MA, Rathenborg P, Brasso K, Borre M, Iversen P.
    Scand J Urol; 2014 Jun; 48(3):268-75. PubMed ID: 24255983
    [Abstract] [Full Text] [Related]

  • 12. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
    de Wit R, de Bono J, Sternberg CN, Fizazi K, Tombal B, Wülfing C, Kramer G, Eymard JC, Bamias A, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Ozatilgan A, Geffriaud-Ricouard C, Castellano D, CARD Investigators.
    N Engl J Med; 2019 Dec 26; 381(26):2506-2518. PubMed ID: 31566937
    [Abstract] [Full Text] [Related]

  • 13. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.
    Bianchini D, Lorente D, Rodriguez-Vida A, Omlin A, Pezaro C, Ferraldeschi R, Zivi A, Attard G, Chowdhury S, de Bono JS.
    Eur J Cancer; 2014 Jan 26; 50(1):78-84. PubMed ID: 24074764
    [Abstract] [Full Text] [Related]

  • 14. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    Smith MR, Saad F, Rathkopf DE, Mulders PFA, de Bono JS, Small EJ, Shore ND, Fizazi K, Kheoh T, Li J, De Porre P, Todd MB, Yu MK, Ryan CJ.
    Eur Urol; 2017 Jul 26; 72(1):10-13. PubMed ID: 28314611
    [Abstract] [Full Text] [Related]

  • 15. Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer.
    Montgomery B, Eisenberger MA, Rettig MB, Chu F, Pili R, Stephenson JJ, Vogelzang NJ, Koletsky AJ, Nordquist LT, Edenfield WJ, Mamlouk K, Ferrante KJ, Taplin ME.
    Clin Cancer Res; 2016 Mar 15; 22(6):1356-63. PubMed ID: 26527750
    [Abstract] [Full Text] [Related]

  • 16. Enzalutamide versus abiraterone as a first-line endocrine therapy for castration-resistant prostate cancer (ENABLE study for PCa): a study protocol for a multicenter randomized phase III trial.
    Izumi K, Mizokami A, Namiki M, Inoue S, Tanaka N, Yoshio Y, Ishibashi K, Kamiyama M, Kawai N, Enokida H, Shima T, Takahara S.
    BMC Cancer; 2017 Oct 10; 17(1):677. PubMed ID: 29017493
    [Abstract] [Full Text] [Related]

  • 17. Serum testosterone level is a useful biomarker for determining the optimal treatment for castration-resistant prostate cancer.
    Hashimoto K, Tabata H, Shindo T, Tanaka T, Hashimoto J, Inoue R, Muranaka T, Hotta H, Yanase M, Kunishima Y, Takahashi A, Masumori N, Sapporo Medical University Urologic Oncology Consortium (SUOC).
    Urol Oncol; 2019 Jul 10; 37(7):485-491. PubMed ID: 31103335
    [Abstract] [Full Text] [Related]

  • 18. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
    Seitz AK, Thoene S, Bietenbeck A, Nawroth R, Tauber R, Thalgott M, Schmid S, Secci R, Retz M, Gschwend JE, Ruland J, Winter C, Heck MM.
    Eur Urol; 2017 Nov 10; 72(5):828-834. PubMed ID: 28818355
    [Abstract] [Full Text] [Related]

  • 19. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
    Suzman DL, Luber B, Schweizer MT, Nadal R, Antonarakis ES.
    Prostate; 2014 Sep 10; 74(13):1278-85. PubMed ID: 25053178
    [Abstract] [Full Text] [Related]

  • 20. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
    Fizazi K, Kramer G, Eymard JC, Sternberg CN, de Bono J, Castellano D, Tombal B, Wülfing C, Liontos M, Carles J, Iacovelli R, Melichar B, Sverrisdóttir Á, Theodore C, Feyerabend S, Helissey C, Oudard S, Facchini G, Poole EM, Ozatilgan A, Geffriaud-Ricouard C, Bensfia S, de Wit R.
    Lancet Oncol; 2020 Nov 10; 21(11):1513-1525. PubMed ID: 32926841
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.